Evidence map›Paper›PMID 19535442›Full record

ArticleJournal of virology2009

Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells.

Michael L Vetter, Richard T D'Aquila

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 31 citations in OpenAlex.

  1. The role of CD4MedComm · 2023
    Review
  2. Article
  3. Review
  4. Article
  5. APOBEC3 Proteins in Viral Immunity.Journal of immunology (Baltimore, Md. : 1950) · 2015
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. APOBEC3G: a double agent in defense.Trends in biochemical sciences · 2011
    Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Michael L VetterDepartment of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Richard T D'Aquila
Vanderbilt University · US

Funding

VIROLOGY COREP30AI054999 · NIAID · VANDERBILT UNIVERSITY · PI D'AQUILA, RICHARD · 2003 to 2011
$10.3M
NUCLEOSIDE RESISTANCE OF THE HIV-1 REVERSE TRANSCRIPTASER01AI029193 · NIAID · VANDERBILT UNIVERSITY · PI D'AQUILA, RICHARD T · 1990 to 2007
$2.8M
HIV/AIDS Research Training ProgramT32AI060571 · NIAID · VANDERBILT UNIVERSITY · PI AIKEN, CHRISTOPHER R · 2004 to 2008
$1.1M
NIAID NIH HHS P30 AI054999NIAID NIH HHS P30 AI 54999NIAID NIH HHS R01 AI029193NIAID NIH HHS R01 AI 29193NIAID NIH HHS T32 AI 060571NIAID NIH HHS T32 AI060571
6 · The paper itself

Abstract

Cytoplasmic APOBEC3G has been reported to block wild-type human immunodeficiency virus type 1 (HIV-1) infection in some primary cells. It is not known whether cytoplasmic APOBEC3G has residual activity in activated T cells, even though virion-packaged APOBEC3G does restrict HIV-1 in activated T cells. Because we found that APOBEC3G expression is greater in activated CD4(+) T-helper type 1 (Th1) lymphocytes than in T-helper type 2 (Th2) lymphocytes, we hypothesized that residual target cell restriction of incoming Vif-positive virions that lack APOBEC3G, if present, would be greater in Th1 than Th2 lymphocytes. Infection of activated Th1 cells with APOBEC3-negative virions did result in decreased amounts of early and late reverse transcription products and integrated virus relative to infection of activated Th2 cells. Two-long terminal repeat (2-LTR) circles, which are formed in the nucleus when reverse transcripts do not integrate, were increased after APOBEC3-negative virus infection of activated Th1 cells relative to infection of activated Th2 cells. In contrast, 2-LTR circle forms were decreased after infection of APOBEC3G-negative cells with APOBEC3G-containing virions relative to APOBEC3G-negative virions and with Th1 cell-produced virions relative to Th2 cell-produced virions. Increasing APOBEC3G in Th2 cells and decreasing APOBEC3G in Th1 cells modulated the target cell phenotypes, indicating causation by APOBEC3G. The comparison between activated Th1 and Th2 cells indicates that cytoplasmic APOBEC3G in activated Th1 cells partially restricts reverse transcription and integration of incoming Vif-positive, APOBEC3G-negative HIV-1. The differing effects of cytoplasmic and virion-packaged APOBEC3G on 2-LTR circle formation indicate a difference in their antiviral mechanisms.

Indexed as

Reverse TranscriptionVirus ReplicationAPOBEC-3G DeaminaseCell NucleusCytidine DeaminaseDNA, CircularHIV-1HumansTerminal Repeat SequencesTh1 CellsTh2 CellsVirus IntegrationAPOBEC-3G DeaminaseAPOBEC3G protein, humanCytidine DeaminaseDNA, Circular

Identifiers

PMID19535442
PMCPMC2738200
OpenAlexW2049365377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.